Pfizer Company Profile

✉ Email this page to a colleague

PFIZER has one hundred and ninety-five approved drugs.

There are forty-nine US patents protecting PFIZER drugs. There is one tentative approval on PFIZER drugs.

There are one thousand and twenty-seven patent family members on PFIZER drugs in seventy countries and two hundred and sixty-one supplementary protection certificates in nineteen countries.

International Patents:	1027
US Patents:	49
Tradenames:	159
Ingredients:	130
NDAs:	195
Drug Master File Entries:	3
Patent Litigation for Pfizer:	See patent lawsuits for Pfizer
PTAB Cases with Pfizer as petitioner:	See PTAB cases with Pfizer as petitioner

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	VIZIMPRO	dacomitinib	TABLET;ORAL	211288-002	Sep 27, 2018		RX	Yes	No	8,623,883	⤷ Sign Up				⤷ Sign Up
Pfizer	CAVERJECT IMPULSE	alprostadil	INJECTABLE;INJECTION	021212-002	Jun 11, 2002		RX	No	No		⤷ Sign Up				⤷ Sign Up
Pfizer Pharms	ACCUPRIL	quinapril hydrochloride	TABLET;ORAL	019885-004	Nov 19, 1991		DISCN	Yes	No		⤷ Sign Up				⤷ Sign Up
Pfizer	ZITHROMAX	azithromycin	CAPSULE;ORAL	050670-001	Nov 1, 1991		DISCN	Yes	No		⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pfizer	XELJANZ XR	tofacitinib citrate	TABLET, EXTENDED RELEASE;ORAL	208246-002	Dec 12, 2019	7,265,221	⤷ Sign Up
Pfizer	COVERA-HS	verapamil hydrochloride	TABLET, EXTENDED RELEASE;ORAL	020552-002	Feb 26, 1996	5,200,196	⤷ Sign Up
Pfizer	MICRONASE	glyburide	TABLET;ORAL	017498-002	May 1, 1984	3,454,635	⤷ Sign Up
Pfizer	IBRANCE	palbociclib	CAPSULE;ORAL	207103-003	Feb 3, 2015	6,936,612	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Extended-release Tablets	4 mg and 8 mg	➤ Subscribe	2012-10-31
➤ Subscribe	Injection	20 mg/mL, 2 mL and 5 mL vials	➤ Subscribe	2004-07-26
➤ Subscribe	Capsules	5 mg and 10 mg	➤ Subscribe	2005-06-21
➤ Subscribe	For Injection	500 mg/vial	➤ Subscribe	2011-06-17
➤ Subscribe	Oral Suspension	100 mg/5 mL	➤ Subscribe	2009-08-03
➤ Subscribe	Injection	2 mg/mL, 100 mL bag	➤ Subscribe	2009-12-29
➤ Subscribe	Tablets	5 mg	➤ Subscribe	2016-11-07
➤ Subscribe	Delayed-release Tablets	50 mg/0.2 mg	➤ Subscribe	2009-06-29
➤ Subscribe	Extended-release Tablets	11 mg	➤ Subscribe	2016-11-07
➤ Subscribe	Capsules	20 mg, 40 mg, 60 mg and 80 mg	➤ Subscribe	2005-02-07
➤ Subscribe	Capsules	75 mg, 100 mg and 125 mg	➤ Subscribe	2019-02-04
➤ Subscribe	Capsules	0.125 mg, 0.25 mg, and 0.5 mg	➤ Subscribe	2014-05-01
➤ Subscribe	Tablets	600 mg	➤ Subscribe	2005-12-21
➤ Subscribe	Injection	2 mg/mL, 300 mL bag	➤ Subscribe	2009-09-01
➤ Subscribe	Tablets	1 g	➤ Subscribe	2005-08-23
➤ Subscribe	Delayed-release Tablets	75 mg/0.2 mg	➤ Subscribe	2008-11-28

Subscribe to access the full database, or Sign Up
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2822953	2019034	Norway	⤷ Sign Up	PRODUCT NAME: LORLATINIB; REG. NO/DATE: EU/1/19/1355 20190523
2767537	LUC00140	Luxembourg	⤷ Sign Up	PRODUCT NAME: TALAZOPARIB, EVENTUELLEMENT SOUS LA FORME D'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE; AUTHORISATION NUMBER AND DATE: EU/1/19/1377 20190624
1746976	17C1027	France	⤷ Sign Up	PRODUCT NAME: SEL DE SUCROSOFATE D'IRINOTECAN; REGISTRATION NO/DATE: EU/1/16/1130 20161018
2822953	C20190036 00302	Estonia	⤷ Sign Up	PRODUCT NAME: LORLATINIIB;REG NO/DATE: EU/1/19/1355 08.05.2019
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.